Shamburg News · 8-K filed Nov 16, 2026, 4:17 PM EST

Aytu BioPharma Reports Fiscal 2027 First Quarter Results and Pending Rosemont Merger

AYTU · AYTU BIOPHARMA, INC

  • Earnings
  • Acquisition
  • Materiality: high

Aytu BioPharma reported net revenue of $14.8 million for the fiscal 2027 first quarter ended September 30, 2026, up 6.9% from $13.9 million, and a net loss of ($3.9) million, or ($0.20) per share. Adjusted EBITDA was ($2.6) million, compared with ($0.6) million a year earlier. The company also disclosed a definitive merger agreement under which Rosemont Pharmaceuticals Holdings would acquire Aytu through a cash tender offer at $2.70 per share, representing total consideration of approximately $56 million on a fully-diluted basis.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001437749-26-037176.

Written from the filing by Shamburg Markets. Figures are as reported by the company.